<?xml version='1.0' encoding='utf-8'?>
<document id="28327633"><sentence text="Cardiac drug-drug interaction between HCV-NS5B pronucleotide inhibitors and amiodarone is determined by their specific diastereochemistry."><entity charOffset="76-86" id="DDI-PubMed.28327633.s1.e0" text="amiodarone" /></sentence><sentence text="Severe bradycardia/bradyarrhythmia following coadministration of the HCV-NS5B prodrug sofosbuvir with amiodarone was recently reported"><entity charOffset="86-96" id="DDI-PubMed.28327633.s2.e0" text="sofosbuvir" /><entity charOffset="102-112" id="DDI-PubMed.28327633.s2.e1" text="amiodarone" /><pair ddi="false" e1="DDI-PubMed.28327633.s2.e0" e2="DDI-PubMed.28327633.s2.e0" /><pair ddi="false" e1="DDI-PubMed.28327633.s2.e0" e2="DDI-PubMed.28327633.s2.e1" /></sentence><sentence text=" Our previous preclinical in vivo experiments demonstrated that only certain HCV-NS5B prodrugs elicit bradycardia when combined with amiodarone"><entity charOffset="133-143" id="DDI-PubMed.28327633.s3.e0" text="amiodarone" /></sentence><sentence text=" In this study, we evaluate the impact of HCV-NS5B prodrug phosphoramidate diastereochemistry (D-/L-alanine, R-/S-phosphoryl) in vitro and in vivo"><entity charOffset="109-124" id="DDI-PubMed.28327633.s4.e0" text="R-/S-phosphoryl" /></sentence><sentence text=" Co-applied with amiodarone, L-ala,SP prodrugs increased beating rate and decreased beat amplitude in human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs), but D-ala,RP produgs, including MK-3682, did not"><entity charOffset="17-27" id="DDI-PubMed.28327633.s5.e0" text="amiodarone" /><entity charOffset="29-37" id="DDI-PubMed.28327633.s5.e1" text="L-ala,SP" /><pair ddi="false" e1="DDI-PubMed.28327633.s5.e0" e2="DDI-PubMed.28327633.s5.e0" /><pair ddi="false" e1="DDI-PubMed.28327633.s5.e0" e2="DDI-PubMed.28327633.s5.e1" /></sentence><sentence text=" Stereochemical selectivity on emerging bradycardia was confirmed in vivo" /><sentence text=" Diastereomer pairs entered cells equally well, and there was no difference in intracellular accumulation of L-ala,SP metabolites ± amiodarone, but no D-ala,RP metabolites were detected" /><sentence text=" Cathepsin A (CatA) inhibitors attenuated L-ala,SP prodrug metabolite formation, yet exacerbated L-ala,SP + amiodarone effects, implicating the prodrugs in these effects"><entity charOffset="97-118" id="DDI-PubMed.28327633.s8.e0" text="L-ala,SP + amiodarone" /></sentence><sentence text=" Experiments indicate that pharmacological effects and metabolic conversion to UTP analog are L-ala,SP prodrug-dependent in cardiomyocytes"><entity charOffset="79-82" id="DDI-PubMed.28327633.s9.e0" text="UTP" /><entity charOffset="94-102" id="DDI-PubMed.28327633.s9.e1" text="L-ala,SP" /><pair ddi="false" e1="DDI-PubMed.28327633.s9.e0" e2="DDI-PubMed.28327633.s9.e0" /><pair ddi="false" e1="DDI-PubMed.28327633.s9.e0" e2="DDI-PubMed.28327633.s9.e1" /></sentence><sentence text="" /></document>